Supplementary Table S1: Life tables for local and distant recurrences, progression-free survival and overall survival.

	Local recurrence		Distant recurrence	
	ICRU	**3D**	**ICRU**	**3D**
1 year	5.7% (2.4-13.0%)	4.8% (1.2-17.7%)	13.2% (7.7-22.1%)	18.8% (9.9-34.1%)
2 years	11.0% (5.9-20.2%)	8.1% (2.6-23.3%)	18.2% (11.5-28.0%)	31.6% (19.1-49.3%)
3 years	11.0% (5.9-20.2%)	8.0% (2.6-23.3%)	23.7% (15.9-34.4%)	36.6% (22.4-56.0%)
4 years	12.7% (7.0-22.6%)	8.0% (2.6-23.3%)	28.2% (19.6-39.6%)	36.6% (22.4-56.0%)
5 years	12.7% (7.0-22.6%)	8.0% (2.6-23.3%)	28.2% (19.6-39.6%)	36.6% (22.4-56.0%)
6 years	12.7% (7.0-22.6%)	8.0% (2.6-23.3%)	28.2% (19.6-39.6%)	36.6% (22.4-56.0%)

	Locoregional control		Distant control	
	ICRU	**3D**	**ICRU**	**3D**
3 years	89.0% (79.8-94.1%)	92.0% (76.7-97.4%)	76.3% (65.6-84.1%)	63.4% (44.0-77.6%)
5 years	87.3% (77.4-93.0%)	92.0% (76.7-97.4%)	71.8% (60.4-80.4%)	63.4% (44.0-77.6%)

	FFS		OS	
	ICRU	**3D**	**ICRU**	**3D**
1 year	82.6% (73.2-89.0%)	79.1% (63.6-88.5%)	90.3% (82.2-94.8%)	90.8% (77.3-96.5%)
2 years	73.0% (62.4-81.0%)	66.7% (49.2-79.3%)	83.2% (73.7-89.6%)	87.8% (73.0-94.8%)
3 years	69.1% (58.2-77.7%)	61.7% (42.8-76.0%)	76.7% (66.2-84.4%)	73.6% (52.1-86.6%)
4 years	63.7% (52.4-73.0%)	61.7% (42.8-76.0%)	72.4% (61.3-80.8%)	73.6% (52.1-86.6%)
5 years	63.7% (52.4-73.0%)	61.7% (42.8-76.0%)	70.8% (59.4-79.5%)	73.6% (52.1-86.6%)
6 years	63.7% (52.4-73.0%)	61.7% (42.8-76.0%)	70.8% (59.4-79.5%)	73.6% (52.1-86.6%)

Supplementary Figure S1: Higher clinical stage significantly predicts for worse overall survival.

Death events were recorded per stage group and analyzed by multivariable Cox regression adjusted for choice of BT technique, age, histology, location of positive lymph nodes, and EBRT/BT dose. Hazard ratio = 1.64 (95% CI 1.06-2.53)